- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04020653
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
A Pilot, Double-blind, Randomized, Parallel-group, Placebo-controlled, Exploratory Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 75 patients will be randomized in a 1:2:2 ratio to 3 arms:
Arm 1: placebo+ACT group (15 patients)
Arm 2: 5 ALA/SFC+Placebo+ACT twice daily (BID) (30 patients)
Arm 3: 5-ALA/SFC+Placebo+ACT once daily (QD) (30 patients)
The study duration will be a maximum of 98 days with treatment period of 7 days and follow-up period of 91 days.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients of 18 to 60 years inclusive.
- Weighing 35 to 90 kg.
- Women with child bearing potential willing to give consent for pregnancy test.
Presence of symptomatic uncomplicated malaria of all species inclusive with a diagnosis confirmed by:
A. Microscopically confirmed parasite infection, between 500 and 100,000 asexual parasite count/μL of blood.
B. Fever, as defined by axillary/tympanic of ≥37.5°C within 24 hours before randomization (must be documented).
- Patients must be willing and able to give written informed consent and comply with all study visits and procedures. If a patient cannot read informed consent and/or write a signature, an impartial witness who speaks the language of the patient must be present during the entire informed consent process and discussion with the patient.
Exclusion Criteria:
- Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization (WHO) Criteria 2010.
- Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment.
- Known history of photo-hypersensitivity, porphyria, or hemochromatosis.
- Have taken any medication with antimalarial or antibiotic with antimalarial effect within 14 days before randomization.
- Received an investigational drug within the past 28 days.
- Patients whose Hemoglobin (Hb) level is lower than 8 g/dL.
- Liver function tests (aspartate aminotransferase/alanine aminotransferase [AST/ALT] levels) more than 2.5 times upper limit of normal values.
- Known human immunodeficiency virus (HIV) or Hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) positive, testing is not required.
- Known significant renal impairment as indicated by serum creatinine of ≥1.4 mg/dL or estimated glomerular filtration rate (eGFR) of <45 mL/min.
- Known history of hypersensitivity, allergic or adverse reactions to 5-aminolevulinic acid and sodium ferrous citrate.
- Presence or history of uncontrolled systemic disease.
- Female patients who are pregnant or breast-feeding.
- Any other condition in the opinion of the investigator makes the patient unsuitable for study
- Received any medication specified as contraindication for ACT or affecting blood concentration of ACT within 5 times the half-life of each medication before the first dose of study medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo + ACT
Patients will receive placebo for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
|
Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT.
ACT will be supplied as a combination tablet.
Other Names:
Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
|
Experimental: 5 ALA/SFC+placebo+ACT BID
5-ALA HCl 300 mg and SFC 236 mg will be administered BID for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl+Placebo and SFC+Placebo at odd number of study medication dosing (Dose 1, 3, 5, 7, 9, 11, 13) and only 5-ALA HCl and SFC at even numbers of study medication dosing (Dose 2, 4, 6, 8, 10,12, 14). |
Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT.
ACT will be supplied as a combination tablet.
Other Names:
Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
SFC 118 mg capsules will be given to the patients as 236 mg BID
|
Experimental: 5-ALA/SFC+placebo+ACT QD
5-ALA HCl 600 mg and SFC 472 mg will be administered QD in the morning or evening for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl and SFC at odd number of study medication dosing (Dose 1, 3, 5, 7) and placebo at even numbers of study medication dosing (Dose 2, 4, 6).
|
Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT.
ACT will be supplied as a combination tablet.
Other Names:
Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
SFC 118 mg capsules will be given to the patients as 472 mg QD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse events
Time Frame: From screening visit (Day -1) untill the Follow-up Visit (Day 98)
|
Number of patients with any adverse events or clinically significant abnormal laboratory parameters to investigate safety and tolerability of 5-ALA HCl and SFC in simultaneous administration with ACT.
|
From screening visit (Day -1) untill the Follow-up Visit (Day 98)
|
Cure rate on Day 28
Time Frame: Day 28
|
Cure rate is defined as the proportion of patients with polymerase chain reaction (PCR)-corrected Adequate Clinical and Parasitological Response (ACPR).
PCR-corrected ACPR is defined as patients with clearance of asexual parasites within 28 days of initiation of study medication and without recrudescence within 28 days.
Cure rate to investigate the preliminary efficacy of 5-ALA HCl and SFC in simultaneous administration with ACT.
|
Day 28
|
Parasite Clearance Time
Time Frame: Every 4 hours for 72 hours from Day 1 to Day 7 until 4 consecutive negative readings
|
Time from first dosing to time of first of 4 consecutive readings with zero parasite count in blood.
Calculated based on parasite count in blood every 4 hours after the start of study medication for 72 hours until there are 4 consecutive negative readings.
|
Every 4 hours for 72 hours from Day 1 to Day 7 until 4 consecutive negative readings
|
Fever Reduction Time
Time Frame: Every 4 hours for 72 hours from Day 1 to Day 7
|
Time to Fever Reduction is defined as the time from first dosing to first normal reading of temperature (<37.5 °C) for two consecutive normal temperature reading plus confirmed normal temperature every 4 hours after the start of study medication for 72 hours
|
Every 4 hours for 72 hours from Day 1 to Day 7
|
Gametocyte Clearance Time
Time Frame: Day 1 to Day 7 + 24 hours
|
Time from the first dose until first total and continued disappearance of gametocytes which remains at least a further 24 hours
|
Day 1 to Day 7 + 24 hours
|
Change in inflammatory parameter: C-reactive protein
Time Frame: Days 1, 3, 7, and 28
|
Change from baseline in C-reactive protein to investigate change in inflammatory parameters
|
Days 1, 3, 7, and 28
|
Change in inflammatory parameter: interleukin-6
Time Frame: Days 1, 3, 7, and 28
|
Change from baseline in interleukin-6 to investigate change in inflammatory parameters
|
Days 1, 3, 7, and 28
|
Change in inflammatory parameter: tumor necrosis factor (TNF)-alpha
Time Frame: Days 1, 3, 7, and 28
|
Change from baseline in tumor necrosis factor (TNF)-alpha to investigate change in inflammatory parameters
|
Days 1, 3, 7, and 28
|
Change in iron metabolism: Serum iron
Time Frame: Days 1, 3, 7, 28, and 98
|
Change from baseline in serum iron to investigate change in iron metabolism parameters
|
Days 1, 3, 7, 28, and 98
|
Change in iron metabolism: Hepcidin
Time Frame: Days 1, 3, 7, 28, and 98
|
Change from baseline in hepcidin to investigate change in iron metabolism parameters
|
Days 1, 3, 7, 28, and 98
|
Change in iron metabolism: total iron binding capacity (TIBC)
Time Frame: Days 1, 3, 7, 28, and 98
|
Change from baseline in total iron binding capacity (TIBC) to investigate change in iron metabolism parameters
|
Days 1, 3, 7, 28, and 98
|
Change in iron metabolism: unsaturated iron binding capacity (UIBC)
Time Frame: Days 1, 3, 7, 28, and 98
|
Change from baseline in unsaturated iron binding capacity (UIBC) to investigate change in iron metabolism parameters
|
Days 1, 3, 7, 28, and 98
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Photosensitizing Agents
- Dermatologic Agents
- Trace Elements
- Micronutrients
- Anticoagulants
- Antiprotozoal Agents
- Antiparasitic Agents
- Chelating Agents
- Sequestering Agents
- Antimalarials
- Calcium Chelating Agents
- Aminolevulinic Acid
- Lumefantrine
- Artemether
- Citric Acid
- Sodium Citrate
- Artemisinins
- Artemisinin
- Ferrous citrate
Other Study ID Numbers
- NPJ005-MAL-0122
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Artemisinin-based combination (ACT)
-
London School of Hygiene and Tropical MedicineSave the ChildrenCompleted
-
Noguchi Memorial Institute for Medical ResearchWorld Health OrganizationCompletedMalaria | Malaria, Asymptomatic ParasitaemiaGhana
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Clinton Health... and other collaboratorsCompletedMalaria | Febrile IllnessNigeria
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Clinton Health... and other collaboratorsCompletedMalaria | Febrile IllnessKenya
-
Region SkaneWithdrawnCancer | Psychological DistressSweden
-
Istituto Auxologico ItalianoCompleted
-
University of CyprusUniversity of CreteUnknown
-
Ministry of Health, BhutanMenzies School of Health Research; Asia Pacific Malaria Elimination NetworkUnknown
-
University of Social Sciences and Humanities, WarsawNational Science Centre, PolandNot yet recruitingHematopoietic Cell Transplantation Recipient | Acceptance and Commitment TherapyPoland
-
University of AarhusKarolinska Institutet; Aarhus University HospitalCompleted